NASDAQ:VRAYViewray Stock Price, Forecast & News

Viewray's stock was trading at $1.69 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, VRAY stock has increased by 91.1% and is now trading at $3.23.
View which stocks have been most impacted by Coronavirus.

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Viewray in the last year. There are currently 1 sell rating, 3 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Viewray.

Viewray is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for Viewray.

Viewray Inc (NASDAQ:VRAY) issued its quarterly earnings results on Thursday, July, 30th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.16) by $0.02. The business had revenue of $14.22 million for the quarter, compared to analysts' expectations of $5.81 million. Viewray had a negative return on equity of 63.41% and a negative net margin of 166.74%.
View Viewray's earnings history.

10 brokerages have issued 12 month price objectives for Viewray's stock. Their forecasts range from $2.00 to $8.00. On average, they anticipate Viewray's share price to reach $4.83 in the next twelve months. This suggests a possible upside of 49.6% from the stock's current price.
View analysts' price targets for Viewray.

Media headlines about VRAY stock have trended very negative this week, according to InfoTrie Sentiment. The research firm identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Viewray earned a daily sentiment score of -3.3 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next few days.
View the latest news about Viewray.

Some companies that are related to Viewray include InMode (INMD), BioLife Solutions (BLFS), Natus Medical (NTUS), Zynex (ZYXI), AxoGen (AXGN), TransMedics Group (TMDX), Semler Scientific (SMLR), Stereotaxis (STXS), Cutera (CUTR), BioSig Technologies (BSGM), Fonar (FONR), Edap Tms (EDAP), electroCore (ECOR), Soleno Therapeutics (SLNO) and Fc Global Realty (FCRE).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Viewray investors own include Alibaba Group (BABA), Amarin (AMRN), Advanced Micro Devices (AMD), Sorrento Therapeutics (SRNE), Crispr Therapeutics (CRSP), Corbus Pharmaceuticals (CRBP), Viking Therapeutics (VKTX), Verastem (VSTM), Anavex Life Sciences (AVXL) and Inovio Pharmaceuticals (INO).

(VRAY) raised $52 million in an initial public offering (IPO) on the week of April 6th 2015. The company issued 4,000,000 shares at $12.00-$14.00 per share. Cowen and Company and Stifel acted as the underwriters for the IPO and BTIG and Brean Capital were co-managers.

Viewray trades on the NASDAQ under the ticker symbol "VRAY."

Viewray's stock is owned by a number of institutional and retail investors. Top institutional investors include Candriam Luxembourg S.C.A. (0.62%), Rhenman & Partners Asset Management AB (0.53%), Essex Investment Management Co. LLC (0.34%), UBS Group AG (0.15%), Swiss National Bank (0.14%) and SG Americas Securities LLC (0.04%). Company insiders that own Viewray stock include Fmr Llc, International Ltd Fosun, James F Dempsey, Orbimed Advisors Llc, Scott William Drake and Shahriar Matin.
View institutional ownership trends for Viewray.

VRAY stock was sold by a variety of institutional investors in the last quarter, including Ieq Capital LLC, Rhenman & Partners Asset Management AB, Essex Investment Management Co. LLC, Swiss National Bank, and Arizona State Retirement System.
View insider buying and selling activity for Viewray.

VRAY stock was bought by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., UBS Group AG, Hodges Capital Management Inc., Principal Financial Group Inc., SG Americas Securities LLC, ProShare Advisors LLC, and Financial Advisory Corp UT ADV. Company insiders that have bought Viewray stock in the last two years include International Ltd Fosun, Scott William Drake, and Shahriar Matin.
View insider buying and selling activity for Viewray.

Shares of VRAY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of VRAY stock can currently be purchased for approximately $3.23.

Viewray has a market capitalization of $477.88 million and generates $87.78 million in revenue each year. The company earns $-120,200,000.00 in net income (profit) each year or ($1.18) on an earnings per share basis.

The official website for Viewray is www.viewray.com.

Viewray's mailing address is 2 THERMO FISHER WAY, OAKWOOD VILLAGE OH, 44146. The company can be reached via phone at 440-703-3210 or via email at [email protected]